Histide AG

Histide is pioneering Recoding Therapeutics™, a novel therapy using non-mutagenic extracellular technologies to direct cell fate.
Based on the universal understanding of the mechanisms underlying mammalian cell behavior, Histide has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.
Histide has developed a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.
Based in Europe, Histide has developed strong international collaborations with leading Universities and Institutes around the globe in order to make its expertise and technology known and promote the Recoding Therapeutics™.